Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Immunisation, Inflammation, Lymphadenopathy, Peripheral swelling
Clinical narrative: booster dose; swollen on her neck or her arm comparable to the size of a baseball ball; swollen on her neck or her arm comparable to the size of a baseball ball; she is only seeing less inflammation as of today 07DEC2021; When will my daughter's lymph nodes return back to normal; had reaction and was very uncomfortable for the booster/ there was a reaction to this booster so badly; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 38 year-old female patient received bnt162b2 (BNT162B2), administration date 01Dec2021 (Batch/Lot number: unknown) at the age of 38 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose, For the first two doses, we did not experience any adverse events".), for Covid-19 Immunization, reaction(s): "did not experience any adverse events"; Bnt162b2 (2nd dose, For the first two doses, we did not experience any adverse events".), for Covid-19 Immunization, reaction(s): "did not experience any adverse events". The following information was reported: IMMUNISATION (non-serious) with onset 01Dec2021, outcome "unknown", described as "booster dose"; SWELLING (non-serious), PERIPHERAL SWELLING (non-serious) all with onset Dec2021, outcome "unknown" and all described as "swollen on her neck or her arm comparable to the size of a baseball ball"; INFLAMMATION (non-serious) with onset Dec2021, outcome "recovering", described as "she is only seeing less inflammation as of today 07DEC2021"; LYMPHADENOPATHY (non-serious) with onset Dec2021, outcome "not recovered", described as "When will my daughter's lymph nodes return back to normal"; FEELING ABNORMAL (non-serious) with onset Dec2021, outcome "unknown", described as "had reaction and was very uncomfortable for the booster/ there was a reaction to this booster so badly".  Additional information: The Pfizer-BioNTech COVID-19 Vaccine is authorized for use as a single booster dose to individuals 18 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19. Fever, headache, fatigue, and pain at the injection site were the most reported side effects, and overall, most side effects were mild to moderate. However, as with the two-shot or single-dose primary series, serious side effects are rare, but may occur. In a clinical study of participants 18 through 55 years of age, adverse reactions following administration of a booster dose included lymphadenopathy (5.2%), nausea (0.7%) and rash (0.3%). In an analysis of all unsolicited adverse events reported following the booster dose, through 1 month after the booster dose, in participants 18 through 55 years of age (N = 306), those assessed as adverse reactions not already captured by solicited local and systemic reactions were lymphadenopathy (n = 16, 5.2%), nausea (n = 2, 0.7%) and rash (n = 1, 0.3%)".  The lot number for bnt162b2 was not provided and will be requested during follow up.